Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Shattuck Labs, Inc.
Shattuck Labs, Inc.
MEI Pharma, Inc.
Seagen Inc.
Crossbow Therapeutics, Inc.
Kura Oncology, Inc.
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Taiho Oncology, Inc.
Genmab
Auron Therapeutics, Inc.
Ossium Health, Inc.
Orca Biosystems, Inc.
Biomea Fusion Inc.
Syndax Pharmaceuticals
Senti Biosciences
Apollo Therapeutics Ltd
Hutchmed
NextCure, Inc.
Newave Pharmaceutical Inc
AvenCell Therapeutics, Inc.
Polaris Group
Byondis B.V.
Cullinan Therapeutics Inc.
GluBio Therapeutics Inc.
MacroGenics
Meryx, Inc.
SystImmune Inc.
AbbVie
Lomond Therapeutics Holdings, Inc.
Marker Therapeutics, Inc.
Kura Oncology, Inc.
medac GmbH
Kyowa Kirin Co., Ltd.
Novartis
Kahr Medical
Nerviano Medical Sciences
Bristol-Myers Squibb
SillaJen, Inc.
Novartis
Novartis
Novartis
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Wugen, Inc.
Sichuan Baili Pharmaceutical Co., Ltd.
Bristol-Myers Squibb
BlossomHill Therapeutics
Schrödinger, Inc.
Sanofi